Dose Escalation Titration Calculator | Mounjaro & Wegovy
Dose escalation titration calculator for Mounjaro & Wegovy
Our Dose Escalation Titration Calculator generates a week-by-week dosing schedule for GLP-1 and dual GIP/GLP-1 receptor agonist medications, including Mounjaro (tirzepatide) and Wegovy (semaglutide), so you can see exactly when each dose increase is due. Gradual titration is a clinically recommended approach designed to reduce side effects such as nausea and vomiting while allowing your body to adjust to each new dose level. Enter your starting dose and injection date below to receive a personalised schedule you can follow alongside your prescriber's guidance.
Dose Escalation & Titration Calculator
Plan your Mounjaro or Wegovy dosing schedule based on your start date and medication type.
| Phase | Dose | Duration | Injection Date | Week Range |
|---|
This schedule is an estimate for general informational purposes only and does not constitute medical advice. Actual titration should always be guided by a UK-registered prescriber based on your individual tolerability, clinical response, and the current Summary of Product Characteristics (SmPC) for your medication. Do not change your dose without consulting your prescriber.
Why a dose escalation titration calculator matters for GLP-1 medications
GLP-1 receptor agonists such as semaglutide (Wegovy) and dual GIP/GLP-1 agonists such as tirzepatide (Mounjaro) are not started at their full therapeutic dose. Clinical trials and prescribing guidelines both demonstrate that beginning at a low dose and increasing it incrementally — a process called titration — significantly reduces gastrointestinal side effects including nausea, vomiting, diarrhoea, and constipation. These side effects are the most common reason patients discontinue treatment early, so a structured escalation plan can help protect long-term adherence.
A dose escalation titration calculator removes the guesswork by mapping out your precise injection dates and corresponding doses across the full titration period. This is particularly useful because the schedules for Mounjaro and Wegovy differ: Mounjaro typically begins at 2.5 mg every four weeks before stepping up through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg, whereas Wegovy starts at 0.25 mg weekly and escalates over approximately 16 weeks to its maintenance dose of 2.4 mg. Having these milestones written down in advance can help patients feel more confident and in control of their treatment.
Understanding the standard titration schedules for Mounjaro and Wegovy
Both medications follow evidence-based titration protocols approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and reflected in NICE guidance. Although your prescriber may adjust these schedules based on your individual tolerance and clinical response, the standard escalation steps below represent the licensed starting points for most adult patients in the UK.
- Mounjaro (tirzepatide): Start at 2.5 mg once weekly for 4 weeks → 5 mg for 4 weeks → 7.5 mg for 4 weeks → 10 mg for 4 weeks → 12.5 mg for 4 weeks → 15 mg maintenance (if tolerated and clinically appropriate).
- Wegovy (semaglutide): Start at 0.25 mg once weekly for 4 weeks → 0.5 mg for 4 weeks → 1 mg for 4 weeks → 1.7 mg for 4 weeks → 2.4 mg maintenance.
- Dose increases should only occur if the current dose is well tolerated — if side effects are significant, your prescriber may recommend staying at the current dose for an additional four weeks before escalating.
- The maintenance dose is the dose at which most patients achieve their optimal balance of efficacy and tolerability; not everyone will need to reach the maximum licensed dose.
- If you miss more than two consecutive doses, consult your prescriber before resuming, as restarting may require stepping back to a lower dose to avoid rebound side effects.
How to use your dose escalation titration calculator results
Once you have generated your schedule using the Dose Escalation Titration Calculator, you will see a dated timeline showing each injection day and the corresponding dose. Print or screenshot this schedule and share it with your prescriber or pharmacist at your next review appointment so they can confirm it aligns with your clinical plan.
Factors that may change your personal titration schedule
The calculator provides a standard protocol based on the licensed prescribing information, but several individual factors can mean your actual schedule differs. These include the severity of gastrointestinal side effects at each dose level, any underlying conditions such as gastroparesis or chronic kidney disease, concomitant medications that interact with GLP-1 pathways, and your prescriber's clinical judgement following regular review appointments. Always treat the calculator output as a starting framework rather than a fixed prescription.
It is also worth noting that some patients on Mounjaro may find their appetite suppression and weight loss goals are met at an intermediate dose — for example 7.5 mg or 10 mg — meaning escalation to 15 mg may not be necessary or appropriate. Your prescriber will assess your response at each review and advise whether continuing to escalate is in your best interest. The schedule generated here can help facilitate that conversation by giving both you and your clinician a clear visual reference point.
Dose escalation titration calculator: frequently asked questions about side effects and what to do if you miss a dose
Managing side effects during titration is one of the most common concerns among patients starting Mounjaro or Wegovy. Nausea tends to peak in the first one to two weeks after each dose increase and then gradually subsides as your body adapts. Eating smaller, lower-fat meals, staying well hydrated, and avoiding lying down immediately after eating can all help. If symptoms are severe or persistent, contact your prescriber — do not simply skip doses without guidance, as this can disrupt the titration process.
Missing a single dose of either medication is not usually cause for alarm. For Wegovy, if fewer than five days have passed since your missed dose, take it as soon as you remember and continue your usual weekly schedule. If more than five days have passed, skip the missed dose entirely and resume on your next scheduled injection day. For Mounjaro, if fewer than four days have passed since your missed dose, take it as soon as possible; if more than four days have passed, skip it and resume your regular weekly schedule. Always refer to the patient information leaflet supplied with your medication and seek advice from your pharmacist or prescriber if you are unsure.
Frequently Asked Questions
Sources
- Mounjaro (tirzepatide) summary of product characteristics Electronic Medicines Compendium (EMC) [accessed 26 August 2026]
- Wegovy (semaglutide) summary of product characteristics Electronic Medicines Compendium (EMC) [accessed 26 August 2026]
- NICE technology appraisal guidance: semaglutide for managing overweight and obesity (TA875) National Institute for Health and Care Excellence (NICE) [accessed 26 August 2026]
- NICE technology appraisal guidance: tirzepatide for managing overweight and obesity (TA1026) National Institute for Health and Care Excellence (NICE) [accessed 26 August 2026]
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial) New England Journal of Medicine, 2021 [accessed 26 August 2026]
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial) New England Journal of Medicine, 2022 [accessed 26 August 2026]
- Weight management: BMI and waist circumference thresholds for intervention NHS England [accessed 26 August 2026]
- Obesity: identification, assessment and management (Clinical guideline CG189) National Institute for Health and Care Excellence (NICE) [accessed 26 August 2026]
- GLP-1 receptor agonists: drug safety update Medicines and Healthcare products Regulatory Agency (MHRA) [accessed 26 August 2026]
- Nauck MA & Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? European Journal of Endocrinology, 2019 [accessed 26 August 2026]
This calculator provides an estimate for general informational purposes only and is not medical advice. Always consult a qualified healthcare professional before making changes to your diet or starting any weight loss treatment.